13 January 2021 in BMC Infectious Diseases
Background: Knowing the number of undetected cases of COVID-19 is important for a better understanding of the spread of the disease. This study analyses the temporal dynamic of detected vs. undetected cases to provide guidance for the interpretation of prevalence studies performed with PCR or antibody tests to estimate the detection rate. Methods: We used an agent-based model to evaluate assumptions on the detection probability ranging from 0.1 to 0.9. For each general detection probability, we derived age-dependent detection probabilities and calibrated the model to reproduce the epidemic wave of COVID-19 in Austria from March 2020 to June 2020. We categorized infected individuals into presymptomatic, symptomatic unconfirmed, confirmed and never detected to observe the simulated dynamic of the detected and undetected cases. Results: The calculation of the age-dependent detection probability ruled values lower than 0.4 as most likely. Furthermore, the proportion of undetected cases depends strongly on the dynamic of the epidemic wave: during the initial upswing, the undetected cases account for a major part of all infected individuals, whereas their share decreases around the peak of the confirmed cases. Conclusions: The results of prevalence studies performed to determine the detection rate of COVID-19 patients should always be interpreted with regard to the current dynamic of the epidemic wave. Applying the method proposed in our analysis, the prevalence study performed in Austria in April 2020 could indicate a detection rate of 0.13, instead of the prevalent ratio of 0.29 between detected and estimated undetected cases at that time.
22 October 2019 in BMC Health Services Research
Background: Chronic obstructive pulmonary disease (COPD) causes significant morbidity and mortality worldwide. Estimation of incidence, prevalence and disease burden through routine insurance data is challenging because of under-diagnosis and under-treatment, particularly for early stage disease in health care systems where outpatient International Classification of Diseases (ICD) diagnoses are not collected. This poses the question of which criteria are commonly applied to identify COPD patients in claims datasets in the absence of ICD diagnoses, and which information can be used as a substitute. The aim of this systematic review is to summarize previously reported methodological approaches for the identification of COPD patients through routine data and to compile potential criteria for the identification of COPD patients if ICD codes are not available.Methods: A systematic literature review was performed in Medline via PubMed and Google Scholar from January 2000 through October 2018, followed by a manual review of the included studies by at least two independent raters. Study characteristics and all identifying criteria used in the studies were systematically extracted from the publications, categorized, and compiled in evidence tables.Results: In total, the systematic search yielded 151 publications. After title and abstract screening, 38 publications were included into the systematic assessment. In these studies, the most frequently used (22/38) criteria set to identify COPD patients included ICD codes, hospitalization, and ambulatory visits. Only four out of 38 studies used methods other than ICD coding. In a significant proportion of studies, the age range of the target population (33/38) and hospitalization (30/38) were provided. Ambulatory data were included in 24, physician claims in 22, and pharmaceutical data in 18 studies. Only five studies used spirometry, two used surgery and one used oxygen therapy.Conclusions: A variety of different criteria is used for the identification of COPD from routine data. The most promising criteria set in data environments where ambulatory diagnosis codes are lacking is the consideration of additional illness-related information with special attention to pharmacotherapy data. Further health services research should focus on the application of more systematic internal and/or external validation approaches.
21 October 2021 in European Journal of Operational Research
In late 2019 a new coronavirus disease (COVID-19) emerged, causing a global pandemic within only a few weeks. A crucial factor in the public health response to pandemics is achieving a short turnaround time between a potential case becoming known, specimen collection and availability of a test result. In this article we address a logistics problem that arises in the context of testing potential cases. We assume that specimens can be collected in two ways: either by means of a mobile test-team or by means of a stationary test-team in a test-centre. After the specimens have been collected they must be delivered to a laboratory in order to be analysed. The problem we address aims at deciding how many test-centres to open and where, how many mobile test-teams to use, which suspected cases to assign to a test-centre and which to visit with a mobile test-team, which specimen to assign to which laboratory, and planning the routes of the mobile test-teams. The objective is to minimise the total cost of opening test-centres and routing mobile test-teams. We introduce this new problem, which we call the contagious disease testing problem (CDTP), and present a mixed-integer linear-programming formulation for it. We propose a large neighbourhood search metaheuristic for solving the CDTP and present an extensive computational study to illustrate its performance. Furthermore, we give managerial insights regarding COVID-19 test logistics, derived from problem instances based on real world data.
27 April 2021 in Data Science Journal